Germany Cell and Gene Therapy Market Insights Forecasts to 2033

• The Germany Cell and Gene Therapy Market Size was valued at USD 0.47 Billion in 2023.
• The Market Size is Growing at a CAGR of 39.90% from 2023 to 2033
• The Germany Cell and Gene Therapy Market Size is Expected to reach USD 13.50 Billion by 2033

The Germany Cell and Gene Therapy Market is anticipated to exceed USD 13.50 billion by 2033, growing at a CAGR of 39.90% from 2023 to 2033. The growing number of biopharmaceutical companies, the development of new therapies, and steadily rising financing in the region are driving the growth of the cell and gene therapy market in the Germany.     

Market Overview

Cell and gene therapies are part of advanced therapy medicinal products that are developed based on genes, tissues, and cells. CAR-T cell therapies, gene therapies, cell-based immunotherapies, and oncolytic virus therapies are the various cell and gene therapy products that are commercially available. There is an increasing development of medical treatment models for the cell and gene therapy field with personalized medicine applications by using advanced therapies for customized healthcare. Cell and gene therapy is experiencing rapid expansion with increased funding and investments, increasing product launches and patent approvals, and increasing cases of diseases like cancer and genetic disorders. The presence of a large pool of target patient populations with chronic diseases such as cancer, genetics, and other complex and rare diseases offers tremendous growth opportunities for cell and gene therapy. Government as well as industrial and academic financing and collaboration among biopharmaceutical companies are leveraging market expansion.

Report Coverage

This research report categorizes the market for the Germany cell and gene therapy market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Cell and gene therapy market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the cell and gene therapy market.

Driving Factors

Pharmaceutical companies are leveraging innovative technologies and patents for the development of advanced personalized treatment of genetic diseases is upsurging the market growth for cell and gene therapy. The increasing collaborations and investment from the regional pharmaceutical market for academic research and projects in cell gene therapies are driving the Germany cell and gene therapy market.

Restraining Factors

The high investment and the time required for R&D of cell and gene therapy as well as the increased complexity of the overall manufacturing process owing to the stringent quality standards are increasing the costs of gene therapy products that resulted in restraining the market. 

Market Segmentation

The Germany Cell and Gene Therapy Market share is classified into product, application, and end-user.

• The gene therapy segment accounted for the largest share of the Germany cell and gene therapy market in 2023.       

Based on the product, the Germany cell and gene therapy market is divided into cell therapy and gene therapy. Among these, the gene therapy segment accounted for the largest share of the Germany cell and gene therapy market in 2023. Gene therapy generates therapeutic effects at the genetic level providing longer-term effects. The growing initiatives for clinical research in the genomics field and the development of advanced therapies are propelling the market growth.

• The oncology segment is anticipated to grow at the fastest CAGR rate during the forecast period.

The Germany cell and gene therapy market is segmented by application into oncology, genetic disorders, dermatology, musculoskeletal, and others. Among these, the oncology segment is anticipated to grow at the fastest CAGR rate during the forecast period. The advancements in gene editing technologies such as CRISPR-Cas9 enabled the precise editing of genes associated with cancer immunotherapy that led to the development of novel gene-induces immunotherapy approaches. The increasing application of fundamental gene therapy approaches for the development of cancer treatment regimes is driving the market.  

• The hospitals segment dominates the market with the largest market share during the forecast period.

The Germany cell and gene therapy market is segmented by end-user into hospitals, cancer care centers, and others. Among these, the hospitals segment dominates the market with the largest market share during the forecast period. Hospital segment are supporting the R&D and clinical trials of cell and gene therapy by increasing collaborations with the key market players. The increasing product launches and the substantial investments in the development of cell and gene therapy are driving the market growth.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Germany cell and gene therapy market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Novartis
• Spark Therapeutics
• Amgen
• Orchard Therapeutics
• Gilead Sciences
• PTC Therapeutics
• Bristol-Myers Squibb
• BioMarin
• Organogenesis
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In May 2024, Merck, a leading science and technology company, signed a definitive agreement to acquire life science company Mirus Bio for US$ 600 million. Mirus Bio is a specialist in the development and commercialization of transfection reagents that play a key role in the production of viral vectors for cell and gene therapies.

• In March 2024, Basel-headquartered Roche AG inaugurated a brand new €90m gene therapy development center in Penzberg near Munich.

Market Segment

This study forecasts revenue at Germany, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Germany Cell and Gene Therapy Market based on the below-mentioned segments:

Germany Cell and Gene Therapy Market, By Product

• Cell Therapy
• Gene Therapy

Germany Cell and Gene Therapy Market, By Application

• Oncology
• Genetic Disorders
• Dermatology
• Musculoskeletal
• Others

Germany Cell and Gene Therapy Market, By End-User

• Hospitals
• Cancer Care Centers
• Others